Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 11/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406954 | 0.87 | LMNA (0.33) | SORDLMNAKDM4ENPC1RAB9A | |
| SCHEMBL6348271 | 0.84 | SORD (0.64) | SORDLMNAKDM4EMAPTHTT | |
| SCHEMBL7488147 | 0.80 | SORD (0.45) | SORDLMNAKDM4ENPC1RAB9A | |
| SCHEMBL6346876 | 0.62 | SORD (0.65) | SORDKDM4EMAPT | |
| SCHEMBL5696320 | 0.59 | SORD (0.40) | SORD | |
| SCHEMBL21387827 | 0.58 | HRH4 (0.39) | SORD | |
| SCHEMBL28618636 | 0.57 | LMNA (0.71) | LMNAKDM4ENPC1RAB9APIK3R1 | |
| SCHEMBL14641243 | 0.57 | MAPK1 (0.49) | KDM4ENPC1RAB9APIK3CAMAPT | |
| SCHEMBL6293147 | 0.56 | SORD (0.70) | SORD | |
| SCHEMBL28761268 | 0.56 | MAPK1 (0.42) | LMNAKDM4EADRB2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894047-B2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030004166-A1 | Novel triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. | 2003-01-02 | — | — | US | disclosed |
| EP-1247809-A2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004166-A1 | Novel triazine compounds useful as sorbitol dehydrogenase inhibitors | SLC5A1, SLC5A2, ADH5 | SORD 4/4885LMNA 2762/4885KDM4E 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.